Related content

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

By Andersen Kenneth Geving   Jensen Maj-Britt   Kehlet Henrik   Gärtner Rune   Eckhoff Lise   Kroman Niels  

Acta Oncologica, Vol. 51, Iss. 8, 2012-11 ,pp. : 1036-1044

Informa Healthcare

Access to resources Recommend Favorite

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

By Abe Hajime  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 487-491

Springer Publishing Company

Access to resources Recommend Favorite

Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study

By            

Oncology Letters, Vol. 3, Iss. 5, 2012-01 ,pp. : 1154-1158

Spandidos Publications

Access to resources Recommend Favorite

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?

By Norum Jan   Holtmon Mari  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 735-741

Informa Healthcare

Access to resources Recommend Favorite

Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer

By Appel Jon M.   Zerahn Bo   Møller Susanne   Christensen Heidi M.   Søgaard Peter   Ejlertsen Bent   Fogh-Andersen Niels   Jensen Benny V.   Nielsen Dorte L.  

Acta Oncologica, Vol. 51, Iss. 8, 2012-11 ,pp. : 1054-1061

Informa Healthcare

Access to resources Recommend Favorite